腾盛博药
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B 2025-11-10 21:30
Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine 2025-11-07 21:30
Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results 2025-08-21 18:02
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China 2025-07-04 08:30
Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss 2025-05-08 08:10
Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification 2025-03-30 19:10
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results 2025-03-21 19:10
Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study 2024-12-31 19:10
Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA 2024-11-19 19:30
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024 2024-06-07 19:00
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies 2024-05-14 07:27
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results 2024-03-22 19:00
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies 2024-02-14 08:07
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer 2024-01-03 20:00
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023 2023-11-14 06:40
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023 2023-11-14 06:40
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B 2023-09-06 18:45
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results 2023-08-22 22:00
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure 2023-07-06 07:25
Brii Biosciences Provides Latest Clinical Development and Corporate Updates 2023-07-06 07:19
1 2 3